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Abstract
Regulatory Mechanism of 1α,25(OH)2D3-Induced 
Osteoclastogenesis by FGF-2
Hyun-A Kim
Department of Dentistry, The Graduate School, Yonsei University
(Directed by Prof. Syng-Ill Lee, D.D.S., Ph.D.)
This study investigated the action of FGF (fibroblast growth 
factor)-2, a potent regulator on the functions of bone and 
cartilage cells. Of FGFs, FGF-2 acts like an autocrine/paracrine 
factor for bone cells. With regards to the effects of FGF-2 on 
bone cells, the response is still controversial in terms of bone 
metabolism, bone formation and bone resorption. To clarify the 
role of FGF-2, osteoclast formation was monitored in coculture 
system, mouse cavarial osteoblastic cells/bone marrow cells in the 
presence of 1α,25(OH)2D3 (VitD3). Numerous TRAP-positive 
cells (80~498) induced by VitD3 were observed in cocultures. 
When FGF-2 (0.1, 1, 10, and 100 ng/ml) was treated to the 
coculture system, VitD3-induced osteoclast formation was inhibited 
by FGF-2 at low concentrations (0.1, 1 ng/ml) while at high 
concentrations (10, 100 ng/ml) stimulated or not changed. It was 
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also confirmed that exposure of FGF-2 to cocultures did not 
show a toxic effect in the entire range of concentration (0.1, 1.0, 
10, and 100 nM), suggesting that the effect of FGF-2 on 
osteoclast formation was caused by its changing the physiological 
activity, not by its direct toxic effect upon the cells. To see the 
effect of FGF-2 on the osteoblastic cells, expressions of RANKL, 
OPG and M-CSF mRNAs were monitored by RT-PCR after 
incubation for 96 hrs. The RANKL mRNA expression level was 
reduced at low concentration. However, FGF-2 did not make any 
remarkable change in OPG and M-CSF mRNA expression. 
Consequently FGF-2, at low concentrations, resulted in the 
decrement of RANKL/OPG ratio. In addition, FGF-2 decreased 
the alkaline phosphatase activity which indicates the osteoblast 
differentiation. A disintegrin and metallo-proteinase (ADAM8), and 
matrix metallo-proteinase 13 (MMP13) which are responsible for 
osteoclast differentiation and degradation of extracellular matrix 
(ECM) respectively were examined by RT-PCR in the presence of 
FGF-2. FGF-2 did not exert any changes in ADAM8 while 
decreased the MMP13 mRNA expression at low concentration. 
Taken all together, these findings suggest that FGF-2 seems to 
have a dual effects on osteoclastogenesis, especially, FGF-2 at 
low concentration decreased osteoclast formation via the 
down-regulation of the RANKL and MMP13 mRNA expressions 
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in osteoblastic cells which in turn inhibits the osteoclast 
formation. 
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Key words : FGF-2, osteoclastogenesis, RANKL, dual effect
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I. Introduction
There are two major groups of cells which are involved in 
skeletal maintenance, osteoblasts and osteoclasts. They are equal 
but opposite function during normal bone remodeling and skeletal 
homeostasis. Osteoblast and osteoclast receives the systemic 
signals from the metabolic products and mechanical strain, which 
follows to mediate the bone formation and resorption. 
Histologically, osteoblast stems from the mesenchymal stem cells 
through a series of progenitor stages to form mature, matrix 
secreting osteoblasts. Osteoclasts are multinucleated cells that 
derive from hematopoietic cells of the monocyte/macrophage 
lineage, and attach to the bone surface. Then the osteoclasts exert 
their own function, secreting hydrogen ions into lacunae via 
ruffled border and an osteoclastic specific organelle, which 
dissolved the bone matrix. As mentioned the above, Osteoblast 
and osteoclast seems to act independently each other, In fact, it 
is generally accepted that osteoclastic bone resorption precedes 
osteoblastic bone formation, suggesting that these two cells are 
closely coupled together.  
Question is what signals governs the coupling between 
osteoblast and osteoclast? Of course, this coupling phenomenon is 
more sophisticated than physiological. Recently, it has been 
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revealed that regulatory interaction occurs in which cells in 
osteoblastic lineage regulate osteoclastic differentiation (Roodman, 
1996; Suda et. al., 1997; Takahashi et. al., 1988). This interaction 
was demonstrated in coculture system which osteoblast or 
osteoblast precursors in the form of stromal cells were cultured 
with bone marrow or spleen cells as sources of osteoclast 
precursors. This resulted in the formation of osteoclast. However, 
when these cells were separated by membrane which is permeable 
to soluble factors but impermeable to cells, no osteoclasts were 
formed. Suda et al. (1992, 1995, 1996) hypothesized that a 
membrane-bound factor, designated as osteoclast differentiation 
factor (ODF),　  is expressed on osteoblasts/stromal cells in 
response to osteotropic factors, and that it transduces a signal 
essential for osteoclastogenesis to osteoclast progenitors through 
cell-to-cell interaction. Recently, osteoclastogenesis-inhibitory factor 
(OCIF, also called osteoprotegerin:OPG) was purified and cloned 
(Tsuda et al., 1997; Yasuda et al., 1998). OPG which was 
initially identified as a novel secreted member of the tumor 
necrosis factor receptor (TNFR) family, and it inhibits 
osteoclastogenesis induced by 1α,25(OH)2D3, PTH, or IL-11. And 
receptor activator of NF-kB ligand (RANKL, also known ODF) is 
a member of the membrane-associated tumor necrosis factor 
(TNF) ligand family, inducing osteoclast differenciation from 
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progenitor cells co-treated with macrophage colony stimulating 
factor (M-CSF). Furthermore, receptor activator of NF-kB 
(RANK) is the signaling receptor essential for RANKL-mediated 
osteoclastogenesis (Nakagawa et. al., 1998). Consequently it is 
believed that RANKL, RANK and OPG play crucial roles in the 
regulation in osteoclastogenesis (Yasuda et. al., 1998; Suda et. al., 
1999; Fig 1). 
As mentioned previously, a coculture system of spleen cells 
with osteoblasts or bone marrow stromal cells has been 
established to produce osteoclasts (Takahashi et al.,1988: Udagawa  
et al.,1989). In the cocultures, osteoclast-like cells (OCLs) are 
formed from spleen cells in the presence of such stimulators of 
bone resorption as interleukin 6 (IL-6), IL-11, parathyroid 
hormone (PTH), prostaglandin E2 (PGE2), and 1
α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] (Suda et al., 1992 ; 
Suda et al.,1995 ; Suda et al.,1996). Of growth factors, FGF is 
involved in bone remodeling (Canalis et al.,1988). Members of 
the fibroblast growth factor (FGFs) family have been shown to be 
important in both normal bone remodeling and in pathologic 
disorders of bone (Baird et al.,1989: Gospodarowicz et al., 1990: 
Noda et al.,1991). Basic fibroblast growth factor (bFGF) is a 
potent regulator of both bone formation (Hurley et al.,1992; 
Canalis et al.,1988) and bone resorption (Simmons et al.,1991). 
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Fig. 1. A model of cellular interactions for osteoclastogenesis.
Stromal cells and osteoblasts (committed OB: stromal cell) 
express RANKL on their cell surface. RANKL can be regulated 
1α,25(OH)2D3 (VitD3), parathyroid hormone (PTH), and cytokines 
which use gp130 as part of their receptor, like IL-6 and 
Oncostatin M (gp130 cytokines).
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bFGF is produced by bone cells (Globus et al.,1989; Hurly 
et al.,1994) and stored in extracellular matrix (Hauschka et 
al.,1986). In addition, it is a potent mitogen for a wide variety of 
cells, including osteoblasts/stromal cells (Canalis E. et al.,1988; 
Globus et al.,1988; Oliver et al.,1990), and a major inhibitor of 
type I collagen synthesis in osteoblastic cells (Hurley MM. et 
al.,1993). Nevertheless, little is known about the physiological 
roles of bFGF in bone remodeling because of its multiple effects 
on bone cells. 
Of FGFs, FGF-2 is well known as a potent regulator of 
functions of bone and cartilage cells. It acts as an 
autocrine/paracrine factor for bone cells (Canalis et al., 1988; 
Globus et al., 1988; Oliver et al., 1990). In regards to the effects 
of FGF-2 on bone cells, it has been reported that the exogenous 
application of FGF-2 has stimulatory effects on bone formation in 
several vivo model. Paradoxically, FGF-2 is also known as a 
potent stimulator of bone resorption (Simmons et al., 1991; 
Kawagushi et al., 1995; Hurley et al., 1998) and is involved in 
joint destruction of rheumatoid arthritis patients (Manabe et al., 
1999). The stimulatory effect of FGF-2 on osteoclast formation is 
mediated by the induction of cyclooxygenase-2, a main regulatory 
enzyme for prostaglandin production in bone, and receptor 
activator of nuclear factor-kB ligand (RANKL), a key 
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membrane-associated molecule regulating osteoclast differentiation 
in osteoblasts (Lacey et al., 1998: Yasuda et al., 1998; Wong et 
al., 1997). On the other hand, there is another possibility that 
FGF-2 acts directly on mature osteoclasts to stimulate bone 
resorption (Kawaguchi et al.,2000; Chikazu et al., 2000) 
Conclusively, the response of FGF-2 to bone cell is still 
controversial as far as osteoclast differentiation concerns.  
Therefore, the understanding about the roles of FGF-2 in both 
physiological and pathological conditions are required for the 
application of FGF-2 to such metabolic bone diseases as 
osteopetrosis and osteoporosis. Theoretically, since 1α,25(OH)2D3 
up-regulates RANKL expression and down-regulates OPG 
expression in osteoblasts/stromal cells, it is suspected that bFGF 
regulates the expression of these two factors as well. Furthermore, 
In the present study, we analyzed the effects of FGF-2 on 1) 
osteoclast formation, 2) alkaline phosphatase activity, 3) the 
expression of RANKL, M-CSF and OPG mRNA and 4) ADAM8, 
MMP13 mRNA expression to evaluate the whether FGF-2 is to 
do with the extracellular matrix metabolism in coculture system.
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Ⅱ. Materials and methods
1. Materials
All routine cell culture media were obtained from 
GIBCO/BRL (Grand Island, NY). The Tartrate-resistant acid 
phosphatase staining kit was purchased from the Sigma Chemical 
Co., Ltd. (St. Louis, MO). FGF-2 was purchased from Promega. 
The ICR mice were purchased from Samtacho Co., Ltd. (Seoul, 
Korea). All other chemicals were of the highest grade 
commercially available.
2. Methods
1) In vitro formation assay of osteoclast
The osteoblast formation assay was carried out as previously 
reported Choi et al. (2001) (Fig. 2). Briefly, the osteoblasts were 
isolated from 1∼2 day-old newborn mice. 30∼50 calvariae were 
digested in 10 ml of an enzyme solution containing 0.2% 
collagenase (Wako, Japan) and 0.1% dispase (GiBCO BRL, 
U.S.A) for 20 minutes at 37 ℃ in a shaking water bath. The 
supernatant was discarded and 10 ml of the enzyme solution was 
added. After shaking at 37 ℃ for 20 minutes, the supernatant 
was collected carefully and transferred to a new tube. This 
digestion of calvariae by collagenase-dispase was repeated three 
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Fig. 2. Coculture system of osteoblast and bone marrow cells. 
Mouse calvarial cells (1×104 cells/well) were cocultured with 
bone marrow cells (1 × 105 cells/well) in α-MEM containing   
10 % fetal calf serum in 48-well plates. All cultures were 
maintained at 37。C in a humidified atmosphere of 5 % CO2 in 
air. After treatment, the cells were subjected to tartrate-resistant 
acid phosphatase (TRAP, a marker enzyme of osteoclasts) 
staining.
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times. The collected was placed in a centrifuge at 1,500×g for 
10 minutes to collect the osteoblastic cells. The cells were 
resuspended in α-MEM containing 10% fetal calf serum (FCS) 
and cultured in 10 cm culture dishes at a concentration of 105 
cells/dish to confluence.  The cells were then detached from the 
culture dishes by trypsin-EDTA, suspended in α-MEM with 10% 
FCS and used for the coculture as osteoblastic cells. 
Femorial and tibial bone marrow cells were collected from 
4-week-old mice. The tibiae and femora were removed and 
dissected free of adhering tissues. The bone ends were removed 
and the marrow cavity was flushed by slowly injecting media at 
one end using a 25-gauge needle. The calvariae and bone marrow 
cells collected were washed and used for the coculture.
Mouse calvarial cells (1×104 cells/well) were cocultured 
with bone marrow cells (1×105 cells/well) in α-MEM containing 
10% fetal calf serum in 48-well plates (Corning Inc., Corning, 
NY). The culture volume was made up to 400 ㎕ per well with 
α-MEM supplemented with 10% fetal calf serum (FCS), in the 
presence of FGF-2. All cultures were maintained at 37 ℃ in a 
humidified atmosphere containing 5% CO2 in air. After treatment, 
the cells were subjected to tartrate-resistant acid phosphatase 
(TRAP, a marker enzyme of osteoclasts) staining.
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2) MTT assays
 MTT (3-[4,5-dimethylthiazol-2-yl-]-2,5-diphenyltetrazolium 
bromide) test uses the principle that tetrazolium salts are reduced 
by a reducing enzyme (succinate dehydrogenase) from the 
mitochondria so that the toxicity of the viable cells and the level 
of cellular proliferation can be measured. MTT was dissolved in 
phosphate-buffered saline (PBS) at 5 mg/ml and filtered to 
remove any insoluble residue. The MTT solution was added 
directly to the assay plates at a rate of 10 ㎕ to 100 ㎕ of the 
cell culture medium. The cells were subsequently incubated for an 
additional 4 hours at 37 ℃. The purple formazan crystals formed 
were dissolved in DMSO(dimetyl sulfoxide) followed by thorough 
mixing. The plates were subsequently read on a spectrophotometer 
at 570 nm (measurement) and 630 nm (reference).  
3) Measurement of alkaline phosphatase activity (ALPase      
 activity)
We tested the effect of FGF-2 on osteoblast differentiation. 
ALPase activity as a marker enzyme of osteoblast was measured 
to evaluate the osteoblast differenciation. Cells were cultured in 
6-well plates for 4 days. The cultured cells which removed from 
plates at every 4 days, washed 2 times with ice-cold 
phosphate-buffered saline (PBS), and the cell layer in each well 
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was scraped into 1 ml of ice-cold PBS. After the addition of 1 
ml of 1% Triton X-100 at 4 ℃, stood on the ice. The 
temperature of the reaction mixture (Sigma 387-A) maintained at 
the assay temperature of 30 ℃. The conversion of substrate by 
ALPase was measured at 405 nm using a microtiter plate reader. 
All samples were blanked against reaction wells previously 
containing conditioned media alone. Protein concentration was 
determined by using Bio-Rad protein assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA) with BSA as the standard 
ALPase activities which were expressed as p-nitrophenol produced 
in millimoles per minute per milligrams of protein.
4) RT-PCR 
Mouse calvarial cells were cultured on 100 mm dishes in α
-MEM containing 10% FBS, 10 ng/ml of VitD3, and varies 
concentration of FGF-2 for  days. The expressions of RANKL, 
OPG, M-CSF and β-actin were evaluated by RT-PCR using total 
RNA isolated from murine osteoblastic cells. The primers used 
were : for RANKL (750 bp) 5'-ATC AGA AGA CAG CAC 
TCA CT-3' (forward), 5'-ATC TAG GAC ATC CAT GCT AAT 
GTT C-3' (reverse); for OPG (636 bp) 5'-TGA GTG TGA GGA 
AGG GCG TTA C-3' (forward), 5'-TTC CTC GTT CTC TCA 
ATC TC-3' (reverse); for M-CSF 5'-ATG ACA AGG CCT GCG 
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TCC GA-3' (forward), 5'-AAG CTC TGG CAG GTG CTC 
CTG-3' (reverse, 395 bp) and 5'-GCC GCC TCC ACC TGT 
AGA ACA-3' (reverse, 286 bp); for β-actin (366 bp) 5'-GGA 
CTC CTA TGG TGG GTG ACG AGG-3' (forward), 5'-GGG 
AGA GCA TAG CCC TCG TAG AT-3' (reverse). In addition, 
ADAM8 and MMP13 mRNA expression were also analysed. The 
following primer were used for ADAM8 (350 bp) 5'-CAT AGT 
GAA ACC AAA GAG GCC-3' (forward), 5'-ATA GGA GCA 
GTG GTA TCT CC-3' (reverse). 
5) Data analysis
The statistical analyses for the differences between the 
groups were carried using one way analysis of the Mann-Whitney 
U test. For all statistical tests, a p value < 0.05 was considered 
to be statistically significant.
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Ⅲ. Results
1. Effect of FGF-2 on the osteoclast formation in co-cultures
We examined whether FGF-2 induces osteoclast formation in 
cocultures of mouse calvariae-derived osteoblastic cells and bone 
marrow cells (Fig. 3 and 4). There were no TRAP-positive cells 
in untreated cocultures (in the absence of VitD3). In contrast, 
numerous TRAP-positive cells were observed in VitD3 or 
FGF-2-treated co-cultures, some of which developed to be 
multinucleated cells. To induce the mature osteoclast from the 
osteoclast precursor cells, 10 nM of 1α,25(OH)2D3 was 
administrated to the coculture system. As shown in Fig. 4, 
multinucleated osteoclasts (MNC) were formed when treated with 
VitD3 in cocultures. When several concentrations of FGF-2 (0.1, 
1, 10, and 100 ng/ml) were added to the coculture system, 
osteoclastogenesis is inhibited at the low concentration of FGF-2 
(0.1, 1 ng/ml) while stimulated or not changed at the high 
concentration of FGF-2 (10, 100 ng/ml). This implies FGF-2 
induced or inhibited osteoclastogenesis, depending upon the dose 
to be treated. However, it might be possible that FGF-2 causes 
cell damage directly without interrupting the normal maturation of 
osteoclasts. To confirm this possibility, we used a viability test 
using MTT method. As shown
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Fig. 3. Osteoclast differentiation in the presence of FGF-2 at 
various concentrations. FGF-2 was added to the osteoblast/bone 
marrow coculture with 10 nM of 1α,25(OH)2D3. After incubation 
for additional 4 days, cells were stained with TRAP staining 
method. TRAP positive multinucleated cells that have more than 
3 nucleus were counted. Vertical bars represent mean±standard 
error.
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Fig. 4. Formation of multi-nucleated osteoclast in the presence of 
FGF-2. Cells were treated with FGF-2 and/or 1α,25(OH)2D3. 
After incubation for additional 4 days, cells were stained with 
TRAP staining method. 
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in Fig. 5, FGF-2 did not exert a toxic effect in the entire range 
of concentration (0.1, 1, 10, and 100 nM). This results suggest 
that the effect of FGF-2 on differentiation was caused by 
changing its physiological activity, not by its direct toxic effect 
upon the cells. 
2. Changes in alkaline phosphatase activity in osteoblastic cells 
To investigate whether the FGF-2 induce the changes in 
osteoblast differentiation, ALPase activity was measured.  As 
shown in Fig. 6, FGF-2 decreased the ALPase activity in 
osteoblastic cells.
3. Alteration of RANKL, OPG and M-CSF mRNA expression 
by FGF-2
Osteoclastogenesis is in part mediated and modulated by 
RANKL, OPG and M-CSF secreted from the osteoblastic cells. 
To confirm the effect of FGF-2 on bone cells, FGF-2 was added 
to the osteoblastic cell, then expressions of RANKL, OPG and 
M-CSF mRNAs were monitored by RT-PCR after 96 hours of 
incubation. FGF-2 at the low concentration (1 ng/ml) resulted in 
the reduction of the RANKL expression level (Fig. 7).
On the other hand, OPG expression (Fig. 8), a decoy receptor, 
which binds to RANKL and blocks RANK 
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Fig. 5. Cell proliferation in the presence of FGF-2 at various 
concentrations. FGF-2 was added to the osteoblast/bone marrow 
coculture with 10 nM of 1α,25(OH)2D3. MTT assays were 
carried out according to the method described in materials and 
methods. Vertical bars represent mean± standard error.
- 21 -
 
Fig. 6. Effect of FGF-2 on alkaline phosphatase activity of 
osteoblastic cells. Various concentrations of FGF-2 were added to 
the osteoblast culture with 10 nM 1α,25(OH)2D3. After 
incubation for additional 4 days, whole cell broth was harvested 
and ALPase activity was assayed according to the method 
described in materials and methods. This is a representative data 
of the experiments.
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A
B
  
Fig. 7. Effect of FGF-2 on the RANKL expression of 
osteoblastic cells. Various concentrations of FGF-2 were added to 
the osteoblast culture with 10 nM 1α,25(OH)2D3. After 
incubation for additional 4 days, total RNA was isolated. mRNAs 
were amplified according to the method described in materials 
and methods. Panels A, agarose gel electrophoresis; B, Relative 
density of RANKL mRNA expression. This is a representative 
data of the experiments.
- 23 -
stimulation, and M-CSF (Fig. 9)  did not change as the FGF-2 
concentration was increased. The mRNA expression ratio of 
RANKL/OPG ratio was decreased at 1 ng/ml of FGF-2 but 
increased at higher concentrations (Fig. 10).
4. ADAM and MMP13 mRNA expression  in osteoblastic cells
With osteoblastic cells, the changes in ADAM8 and MMP13 
mRNA expressions were monitored. Although the concentration of 
FGF-2 that was added to the medium increased the expression of 
ADAM8 mRNA did not show any significant change (Fig. 11). 
In case of MMP13, mRNA expression was repressed only at the 
concentration of 100 ng/ml (Fig. 12). However, any correlation 
between FGF-2 and MMP13 was not detected.
- 24 -
A
B
  
Fig. 8. Effect of FGF-2 on the OPG expression of osteoblastic 
cells. Various concentrations of FGF-2 were added to the 
osteoblast culture with 10 nM 1α,25(OH)2D3. After incubation 
for additional 4 days, total RNA was isolated. mRNAs were 
amplified according to the method described in materials and 
methods. Panels A, agarose gel electrophoresis; B, Relative 
density of OPG mRNA expression. This is a representative data 
of the experiments.
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Fig. 9. Effect of FGF-2 on the M-CSF expression of osteoblastic 
cells. Various concentrations of FGF-2 were added to the 
osteoblast culture with 10 nM 1α,25(OH)2D3. After incubation 
for additional 4 days, total RNA was isolated. mRNAs were 
amplified according to the method described in materials and 
methods. Panels A, agarose gel electrophoresis; B, Relative 
density of M-CSF mRNA expression. This is a representative data 
of the experiments.
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Fig. 10. Relative density of RANKL and OPG mRNA 
expressions. Agarose gel electrophoresis was carried out and 
densities of the bands were analyzed with densitometer. Relative 
ratio of RANKL and OPG were calculated based on the density 
of each band. This is a representative data of the experiments.
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Fig. 11. Effect of FGF-2 on the ADAM8 expression of 
osteoblastic cells. Various concentrations of FGF-2 were added to 
the osteoblast culture with 10 nM 1α,25(OH)2D3. After 
incubation for additional 4 days, total RNA was isolated. mRNAs 
were amplified according to the method described in materials 
and methods. Panels A, agarose gel electrophoresis; B, Relative 
density of ADAM8 mRNA expression. This is a representative 
data of the experiments.
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Fig. 12. Effect of FGF-2 on the MMP13 expression of 
osteoblastic cells. Various concentrations of FGF-2 were added to 
the osteoblast culture with 10 nM 1α,25(OH)2D3. After 
incubation for additional 2 days, total RNA was isolated. mRNAs 
were amplified according to the method described in materials 
and methods. Panels A, agarose gel electrophoresis; B, Relative 
density of MMP13 mRNA expression. This is a representative 
data of the experiments.
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Ⅳ. Discussion
It has been recognized that RANKL expressed on 
osteoblasts/stromal cells mediates an essential signal to osteoclast 
progenitors for their differentiation into active osteoclasts through 
RANK and OPG, a decoy receptor for RANKL, inhibits the 
RANKL signaling as a competitor of RANK (Lacey et al., 1998; 
Hofbauer et al., 2000). With regards to the regulation of 
osteoclastogenesis, the FGF-2 response is controversal or not 
consistent in terms of bone formation and bone resorption. In 
fact, the effect of FGF-2 on the osteoclastogenesis based on 
OPG/RANKL/RANK system is not understood well. Therefore, 
we examined the changes in VitD3-induced osteoclast formation 
by the FGF-2 and evaluate its response by monitoring the 
OPG/RANKL/RANK system in this study. Firstly, a variety of 
FGF-2 concentration (1-100 ng/ml) were treated in coculture 
system. As shown in Fig 3, VitD3-induced osteoclastogenesis was 
inhibited by the low concentration of FGF-2 (0.1, 1 ng/ml), while 
stimulate rather than the inhibition of osteoclastogenesis in the 
case of high concentration of FGF-2 (10 ng/ml). Obviously, the 
VitD3-induced osteoclastogenesis was regulated by FGF-2, showing 
the opposite effects (inhibition or stimulation of osteoclasto- 
genesis) at a low or high concentration of FGF-2. Such a dual 
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effect of FGF-2 on osteoclastogenesis makes the investigators 
confused. For instances, a series of bone metabolism studies in 
vivo have indicated that FGF-2 has stimulatory effect on bone 
formation (Aspenberg et al., 1989: Kawaguchi et al., 1994: 
Kawaguchi et al., 2001). On contrary, Hurley et al. (1998) 
recently reported that FGF-2 (10-8 M/l) induces osteoclast 
formation in mouse bone marrow cultures. Moreover, several lines 
of evidences suggest that FGF-2 (10-9 M) can generate the bone 
resorption (Kawaguchi et al., 2000: Chikazu et al., 2000), 
reflecting the complexity and dual effects of osteoclastogenesis. 
From the all of previous results, FGF-2 might have dual 
effect on bone metabolism (bone formation and bone resorption), 
showing the different response on osteoclastogenesis as a function 
of concentration (Fig. 3). We confirmed the different effects of 
FGF-2 on osteoclastogenesis from the individual repetitive trials 
which showed the same patterns with the dual responses. 
Tentatively, It might be speculated that FGF-2 responses on 
osteoclastogenesis depend upon the concentration to be 
administrated in co-culture system. Although FGF-2 concentration 
is critical to modulate the osteoclastogenesis, we focused on the 
regulation of osteoclastogenesis by low concentration of FGF-2 
which could be near to the ideal concentration in vivo. Again, as 
shown in Fig. 3, FGF-2 at low concentrations inhibited the 
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osteoclastogenesis on the basis of osteoclast formation. Thus we 
have been in search of the regulation in OPG/RANKL/RANK 
system which is essential for the typical osteoclastogenesis.   
The question was what mechanism is involved in the 
inhibition of osteoclastogenesis by FGF-2 at low concentrations. 
Here, FGF-2 decreased the RANKL mRNA expression (Fig. 7), 
while no significant differences on OPG and M-CSF mRNA 
expression were monitored in RT-PCR. With quantitative aspects, 
the inhibitory effect of FGF-2 on RANKL mRNA expression did 
not seem to be consistent with the blocking ability of osteoclast 
formation in response to FGF-2 (Fig. 3). These findings indicate 
other possible routes might be speculated as  regulatory pathways 
of osteoclastogenesis as well as OPG/RANKL/RANK system. 
Recently, alternative pathway with the new concept on the 
regulation of osteoclastogenesis began to be in consideration since 
the possibility for OPG/RANKL/RANK-independent pathway was 
also accepted to explain the osteoclastogenesis induced by 
bacterial LPS (Jiang et al., 2002). Consequently, the osteoblast 
may govern the osteoclastogenesis via not only  OPG/RANKL/ 
RANK system, but also RANKL-independent system (for 
example, LPS) by which osteoclastogenesis is introduced. 
Unlike RANKL mRNA, OPG and M-CSF mRNA was not 
changed by the FGF-2. Of cause, FGF-2 reduced OPG mRNA 
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expression at high concentration, being consistent with stimulation 
of osteoclast formation (Fig. 8). However, we could not found 
any changes in M-CSF at a given FGF-2 concentration (Fig. 9). 
Conclusively FGF-2 decreases the osteoclastogenesis, down- 
regulating primarily the RANKL mRNA in osteoblastic cells, not 
affecting the osteoclast maturation. In regard to osteoblast 
differentiation, ALPase activity also was analysed (Fig. 6). As 
shown in Fig. 6, FGF-2 decreased the ALPase activity in 
osteoblastic cells, suggesting that FGF-2 is not the essential factor 
for the osteoblast differentiation. But it still does not clear how 
the osteoblast differentiation is coupled to osteoclast formation in 
terms of regulation of osteoclastogenesis.  
As described the above, FGF-2 inhibits the RANKL mRNA 
expression in osteoblastic cells. Nevertheless, Kawaguchi et al. 
(2000) demonstrated that the expression of RANKL mRNA was 
up-regulated by FGF-2 in osteoblastic cells. Consistent with the 
results in the Northern blot analysis, 125I-OPG binding analysis 
revealed that treatment of osteoblastic cells with FGF-2 for 6 
days induced RANKL production in the cells, and the production 
was markedly inhibited by addition of NS-398 which is an 
inhibitor of cyclooxygenase-2 (COX-2). Taken together with these 
previous findings, PGE2 stimulates RANKL mRNA expression and 
RANKL production in mouse primary osteoblastic cells, 
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suggesting that FGF-2 stimulates RANKL production in 
osteoblastic cells through COX-2-mediated PG synthesis, and 
induces osteoclastogenesis in the co-cultures. Furthermore, it was 
shown that FGF-2 suppressed OPG expression in osteoblastic cells 
(Kawaguchi et al., 2000). The decrease in OPG mRNA 
expression and OPG production was not recovered by addition of 
NS-398, indicating that the FGF-2-induced suppression of OPG 
expression was not mediated by PG synthesis. In contrast to these 
results, no remarkable changes were observed in OPG mRNA 
expression with various FGF-2 concentrations in this study (Fig. 
8). Accordingly, FGF-2 response on osteoclastogenesis might be 
controversal when it comes to gene expression of RANKL in 
osteoblasts/stromal cells. With the above results, it is clear that 
FGF-2 plays an important role in bone remodeling by modulating 
the production of RANKL in osteoblastic cells. But, further 
studies are required to elucidate the molecular mechanisms by 
which FGF-2 regulates the expression of RANKL and OPG. 
In general, fibroblast growth factors (FGFs) are potent 
mitogens for a wide variety of cells of mesenchymal and 
neuroectodermal origin. FGFs also play a role in the 
differentiation of a variety of cells and are involved in 
morphologenesis, angiogenesis, and development. The FGF family 
now consists of 23 members, FGF-1 to FGF-23, and there are 4 
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structurally related high-affinity receptors (FGFR1 to FGFR4) 
belonging to receptor tyrosine kinases that have an intrinsic 
protein tyrosine kinase activity and elicit tyrosine auto- 
phosphorylation of the receptor. Recent reports showing that 
mutations of FGFRs cause several genetic diseases with severe 
impairment of bone and cartilage formation, such as 
achondroplasia and thana-tophoric dysplasia type II, indicate the 
essential role of FGF signalings on bone and cartilage 
metabolism. The target cells mediating the effects of FGF-2 on 
osteoclast formation in the co-cultures were found to be 
osteoblastic cells, but not osteoclast progenitors. However, some 
studies suggest that  fibroblast growth factor -2 (FGF-2) has an 
osteogenic effect. FGF-2 is synthesized by osteoblasts and 
deposited in bone matrix. This growth factor enhances the 
proliferation of osteoprogenitor and osteoblast-like cells and 
induces formation of bone-like nodules in cultures of bone 
marrow cells. Similar skeletal effects were observed in vivo in 
young and aged rats treated with bFGF. For example, systemic 
injections of the growth factor increased the osteoblast population 
and cancellous bone mass in intact rats. In addition, new bone 
spicules were observed in the marrow cavity of these animals. 
Like the above results, bone metabolism seems to be very 
complicated, and controversal as discussed previously, depending 
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upon the cell type, in vivo or in vitro experiment, and culture 
types. In spite of that, we can evaluate the final destination of 
bone remodeling (bone formation or bone resorption) as a 
RANKL/OPG ratio at a given circumstances. In Fig 10, at a low 
concentration FGF-2 decreased RANKL/OPG ratio, whereas at  
high concentrations increased RANKL/OPG ratio. Besides the 
OPG/RANKL/OPG system, A disintegrin and metallo-proteinase 
(ADAM8), and matrix metalloproteinase 13 (MMP13) which are 
responsible for osteoclast differentiation and degradation of 
extracellular matrix (ECM) respectively were examined by 
RT-PCR in the presence of FGF-2. MMP13 mRNA expression 
was reduced by the treatment of low concentration of FGF-2 
suggesting that FGF-2 could be in charge of the protection of 
collagenase activity. However, no remarkable changes in ADAM8 
was noticed.
In summary, the balance between osteoblast and osteoclast 
functions is regulated systematically by a variety of hormone and 
locally by the production of paracrine factors by osteoblast or 
bone marrow stromal cells that regulate osteoclast functions. The 
development of osteoclast requires the intimate contact between 
osteoblastic stromal cells and osteoclast precursors. RANKL, 
RANK, and OPG recently identified as regulators of 
osteoclastogenesis. Here, FGF-2 at a low concentration resulted in  
- 36 -
the inhibition of osteoclastogenesis by the decrement of 
RANKL/OPG ratio, but FGF-2 at a high concentration stimulates 
the osteoclastogenesis through the enhancement of RANKL/OPG, 
showing the dual effects. Taken all together, these findings 
suggest that FGF-2 on osteoclastogenesis seems to have a dual 
effects by the modulating the RANKL/OPG ratio including the 
MMP13. However, underlying mechanism for the dual effect of  
FGF-2 remains to be solved.
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국문요약
Regulator Mechanism of 1α,25(OH)2D3-Induced 
Osteoclastogenesis by FGF-2
연세대학교 대학원 치의학과
김현아
이 연구는 골세포와 연골세포의 기능에 있어 강력한 조절인자인 
FGF-2의 작용을 규명하였다. 여러 종류의 FGF 중 FGF-2는 골세포에
서 autocrine, 또는 paracrine 방식으로 작용하며, 이것이 골 대사, 골 
형성과 흡수에 미치는 반응에 관해서는 논쟁의 여지가 있다. 따라
서, 쥐의 두개골에서 분리한 조골세포와 골수세포와의 혼합배양에서 
유도되는 파골세포 형성과정 중  FGF-2의 작용을 검토하였다. VitD3
에 의한 파골세포 형성 유도시 다수의 TRAP 양성세포를 관찰할 수 
있었으며, FGF-2 (0.1, 1,10 and 100 ng/ml) 첨가시 낮은 농도 (0.1, 1 
ng/ml)에서는 VitD3에 의하여 유도된 파골세포 형성이 억제되었고 
높은농도 (10, 100 ng/ml)에서는 변화를 보이지 않거나 촉진되었다. 
또한, 실험에 사용된 FGF-2의 모든 농도에서 어떠한 세포독성도 나
타내지 않았다. 따라서, 이는 파골세포 형성의 억제는 직접적인 독
성작용에 의하지 않고 생리적 작용의 변화에 기인한 것임을 나타낸
다. 
FGF-2를 조골세포에 첨가하여 RANKL, OPG 및 M-CSF의 mRNA 
발현을 측정한 결과 낮은 농도에서는 RANKL mRNA발현이  감소하
였으나 OPG와 M-CSF는 큰 변화를 보이지 않았다. 그밖에도 FGF-2
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는 조골세포의 분화정도를 가늠하는 alkaline phosphatase와 세포외기
질의 분해에 관련된 효소인 MMP13 (matrix metalloproteinase 13)의 
mRNA발현을 감소시키고 파골세포 분화와 관련 있는 ADAM8 (A 
disintegrin and metalloprotease)의 발현에는 영향을 미치지 않는 것으
로 나타났다. 이상의 결과로부터, FGF-2는 파골세포 형성과정에 있
어 이중 효과 (dual effect)를 보이며, 특히 낮은 농도에서는 조골세포
의 RANKL과 MMP13의 mRNA발현을 감소시킴으로써 파골세포의 
형성을 억제한다.
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